Effect of high-dose mineralocorticoid receptor antagonist eplerenone on urinary albumin excretion in patients with type 2 diabetes and high cardiovascular risk: Data from the MIRAD trial

Authors:

Abstract
No abstract available

This publication has 37 references indexed in Scilit: